MPM Bioimpact LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), MPM Bioimpact LLC reported 43 stock positions worth $581.7 million. Its top holding was Cullinan Therapeutics (CGEM) at 10.0% of the portfolio, followed by Madrigal Pharmaceuticals (MDGL, 5.7%) and Zai Lab Ltd.-ADR (ZLAB, 5.2%). Compared with Q4 2024, it opened 6 new positions, sold out of 10, added to 26 and reduced 8. The biggest buy was a new position in Madrigal Pharmaceuticals (MDGL) and the biggest sale an exit from Insmed (INSM).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001687078
- Portfolio Value
- $581.7M (Q1 2025)
- SEC Filing
- 0000950123-25-005756 ↗ filed May 15, 2025
Holdings Value
Holdings 43 stocks · $581.7M
| CGEM Cullinan Therapeutics Inc. | 9.95% | 7,648,268 | $57.9M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 5.72% | 100,415 | $33.3M | New |
| ZLAB Zai Lab Ltd.-ADR | 5.18% | 833,659 | $30.1M | Add +4.2% |
| EWTX Edgewise Therapeutics Inc. | 4.18% | 1,105,444 | $24.3M | Add +2.4% |
| LNTH Lantheus Holdings Inc. | 3.90% | 232,387 | $22.7M | Reduce -1.6% |
| PTCT PTC Therapeutics Inc. | 3.85% | 439,977 | $22.4M | Add +1.2% |
| NTRA Natera Inc. | 3.82% | 157,047 | $22.2M | Reduce -2.2% |
| TRVI Trevi Therapeutics Inc. | 3.71% | 3,428,366 | $21.6M | Add +10.8% |
| CRNX Crinetics Pharmaceuticals Inc. | 3.64% | 631,964 | $21.2M | Add +2.4% |
| RNAM Avidity Biosciences Inc. | 3.62% | 714,224 | $21.1M | Add +1.6% |
| GH Guardant Health Inc. | 3.24% | 442,656 | $18.9M | Reduce -2.2% |
| UTHR United Therapeutics Corp. | 3.12% | 58,907 | $18.2M | Add +156.1% |
| SPRY Ars Pharmaceuticals Inc. | 2.84% | 1,313,104 | $16.5M | New |
| CMPX Compass Therapeutics Inc. | 2.76% | 8,442,783 | $16.0M | Reduce -1.5% |
| JANX Janux Therapeutics Inc. | 2.63% | 567,193 | $15.3M | Add +146.6% |
| RARE Ultragenyx Pharmaceutical Inc. | 2.48% | 398,445 | $14.4M | Add +1.9% |
| MLTX Moonlake Immunotherapeutics | 2.12% | 316,049 | $12.3M | Add +0.3% |
| WVE Wave Life Sciences Ltd. | 2.10% | 1,509,580 | $12.2M | Add +1.4% |
| RVMD Revolution Medicines Inc. | 1.93% | 317,083 | $11.2M | Add +1.0% |
| ALKS Alkermes PLC | 1.92% | 337,603 | $11.1M | New |
| OLMA Olema Pharmaceuticals Inc. | 1.89% | 2,930,446 | $11.0M | Add +0.6% |
| RCKT Rocket Pharmaceuticals Inc. | 1.86% | 1,618,265 | $10.8M | Add +58.6% |
| ITOS Iteos Therapeutics Inc. | 1.79% | 1,745,943 | $10.4M | No change |
| RNAC Cartesian Therapeutics Inc. | 1.79% | 790,779 | $10.4M | Add +9.7% |
| TWST Twist Bioscience Corp. | 1.76% | 261,215 | $10.3M | Reduce -2.4% |
| XENE Xenon Pharmaceuticals Inc. | 1.75% | 303,398 | $10.2M | Add +53.8% |
| VERA Vera Therapeutics Inc. | 1.72% | 415,719 | $10.0M | Add +61.3% |
| REPL Replimune Group Inc. | 1.65% | 987,036 | $9.6M | Add +3.9% |
| IOVA Iovance Biotherapeutics Inc. | 1.55% | 2,708,582 | $9.0M | Add +1.3% |
| CNTX Context Therapeutics Inc. | 1.55% | 14,705,882 | $9.0M | No change |
| MBX MBX Biosciences Inc. | 1.44% | 1,132,950 | $8.4M | New |
| NUVB Nuvation Bio Inc. | 1.41% | 4,652,243 | $8.2M | Add +11.7% |
| ORIC Oric Pharmaceuticals Inc. | 1.34% | 1,399,514 | $7.8M | New |
| IDYA Ideaya Biosciences Inc. | 1.21% | 430,161 | $7.0M | Add +3.9% |
| SLDB Solid Biosciences Inc. | 1.04% | 1,642,356 | $6.1M | New |
| RLAY Relay Therapeutics Inc. | 1.03% | 2,295,924 | $6.0M | Add +1.2% |
| STOK Stoke Therapeutics Inc. | 0.79% | 693,988 | $4.6M | Add +1.2% |
| VERU Veru Inc. | 0.56% | 6,592,727 | $3.2M | Add +53.8% |
| HOWL Werewolf Therapeutics Inc. | 0.40% | 2,408,810 | $2.3M | Add +0.9% |
| DSGN Design Therapeutics Inc. | 0.37% | 562,943 | $2.2M | Add +0.6% |
| ADAPY Adaptimmune Therapeutics-ADR | 0.17% | 4,894,344 | $964K | Reduce -4.0% |
| RPTX Repare Therapeutics Inc. | 0.14% | 819,924 | $808K | Reduce -33.4% |
| ALXO Alx Oncology Holdings Inc. | 0.06% | 550,000 | $343K | Reduce -60.5% |
Portfolio Sells Q4 2024 → Q1 2025
| INSM Insmed Inc. | Sold out | 0.00% | −3.82 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −3.46 |
| IRON Disc Medicine Inc. | Sold out | 0.00% | −3.12 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −2.55 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −1.82 |
| ARCT Arcturus Therapeutics Holdin | Sold out | 0.00% | −1.11 |
| AQST Aquestive Therapeutics Inc. | Sold out | 0.00% | −0.81 |
| AXSM Axsome Therapeutics Inc. | Sold out | 0.00% | −0.60 |
| STRO Sutro Biopharma Inc. Com SHS | Sold out | 0.00% | −0.56 |
| ZNTL Zentalis Pharmaceuticals Inc. | Sold out | 0.00% | −0.48 |
| ALXO Alx Oncology Holdings Inc. | Reduce -60.5% | 0.06% | −0.27 |
| ADAPY Adaptimmune Therapeutics-ADR | Reduce -4.0% | 0.17% | −0.22 |
| RPTX Repare Therapeutics Inc. | Reduce -33.4% | 0.14% | −0.09 |
| TWST Twist Bioscience Corp. | Reduce -2.4% | 1.76% | −0.00 |
| NTRA Natera Inc. | Reduce -2.2% | 3.82% | +0.21 |
| LNTH Lantheus Holdings Inc. | Reduce -1.6% | 3.90% | +0.90 |
| CMPX Compass Therapeutics Inc. | Reduce -1.5% | 2.76% | +0.99 |
| GH Guardant Health Inc. | Reduce -2.2% | 3.24% | +1.28 |
Portfolio Buys Q4 2024 → Q1 2025
| MDGL Madrigal Pharmaceuticals Inc. | New | 5.72% | +5.72 |
| SPRY Ars Pharmaceuticals Inc. | New | 2.84% | +2.84 |
| ZLAB Zai Lab Ltd.-ADR | Add +4.2% | 5.18% | +2.21 |
| UTHR United Therapeutics Corp. | Add +156.1% | 3.12% | +1.97 |
| ALKS Alkermes PLC | New | 1.92% | +1.92 |
| TRVI Trevi Therapeutics Inc. | Add +10.8% | 3.71% | +1.90 |
| MBX MBX Biosciences Inc. | New | 1.44% | +1.44 |
| ORIC Oric Pharmaceuticals Inc. | New | 1.34% | +1.34 |
| PTCT PTC Therapeutics Inc. | Add +1.2% | 3.85% | +1.07 |
| SLDB Solid Biosciences Inc. | New | 1.04% | +1.04 |
| JANX Janux Therapeutics Inc. | Add +146.6% | 2.63% | +0.88 |
| RNAM Avidity Biosciences Inc. | Add +1.6% | 3.62% | +0.72 |
| XENE Xenon Pharmaceuticals Inc. | Add +53.8% | 1.75% | +0.65 |
| VERA Vera Therapeutics Inc. | Add +61.3% | 1.72% | +0.17 |
| VERU Veru Inc. | Add +53.8% | 0.56% | +0.16 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +1.9% | 2.48% | +0.14 |
| EWTX Edgewise Therapeutics Inc. | Add +2.4% | 4.18% | +0.09 |
| RCKT Rocket Pharmaceuticals Inc. | Add +58.6% | 1.86% | +0.03 |
| REPL Replimune Group Inc. | Add +3.9% | 1.65% | +0.02 |
| RVMD Revolution Medicines Inc. | Add +1.0% | 1.93% | −0.02 |
| RNAC Cartesian Therapeutics Inc. | Add +9.7% | 1.79% | −0.04 |
| HOWL Werewolf Therapeutics Inc. | Add +0.9% | 0.40% | −0.10 |
| DSGN Design Therapeutics Inc. | Add +0.6% | 0.37% | −0.12 |
| NUVB Nuvation Bio Inc. | Add +11.7% | 1.41% | −0.16 |
| STOK Stoke Therapeutics Inc. | Add +1.2% | 0.79% | −0.28 |
| RLAY Relay Therapeutics Inc. | Add +1.2% | 1.03% | −0.29 |
| IDYA Ideaya Biosciences Inc. | Add +3.9% | 1.21% | −0.30 |
| MLTX Moonlake Immunotherapeutics | Add +0.3% | 2.12% | −0.30 |
| OLMA Olema Pharmaceuticals Inc. | Add +0.6% | 1.89% | −0.52 |
| WVE Wave Life Sciences Ltd. | Add +1.4% | 2.10% | −0.52 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +2.4% | 3.64% | −0.84 |
| IOVA Iovance Biotherapeutics Inc. | Add +1.3% | 1.55% | −1.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $1.6B | CGEM, AKTS, LQDA, RVMD, CORT |
| Q1 2026 | 41 | $1.3B | DBVT, CGEM, AKTS, LQDA, ALMS |
| Q4 2025 | 38 | $874.0M | CGEM, MDGL, LQDA, TRVI, EWTX |
| Q3 2025 | 40 | $610.9M | MDGL, CGEM, RNAM, TRVI, EWTX |
| Q2 2025 | 44 | $577.2M | CGEM, MDGL, ZLAB, GH, SPRY |
| Q1 2025 | 43 | $581.7M | CGEM, MDGL, ZLAB, EWTX, LNTH |
| Q4 2024 | 47 | $704.4M | CGEM, CRNX, EWTX, INSM, NTRA |
| Q3 2024 | 43 | $666.6M | CGEM, INSM, OLMA, RNAM, CRNX |
| Q2 2024 | 44 | $643.5M | CGEM, INSM, OLMA, ITOS, CRNX |
| Q1 2024 | 38 | $622.0M | CGEM, GERN, IOVA, ZNTL, ITOS |